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THIN MELANOMA
BRESLOW THICKNESS ≤1 mm
THICK MELANOMA
BRESLOW THICKNESS >1 mm
Intra-epidermal radial growth phase 
(in situ, pTis)
Invasive vertical growth phase
>1 mm ≤2 mm (pT2)
Micro-invasive radial growth phase without 
regression (pT1) Invasive vertical growth phase>2 mm ≤3 mm (pT3)
Micro-invasive radial growth phase with 
regression (pT1)
Invasive vertical growth phase
>3 mm ≤4 mm (pT3)
Early (≤1 mm) invasive vertical 
growth phase (pT1)
Invasive vertical growth phase
>4 mm (pT4)
a and b specifications are assigned based on ulceration and thickness
a: without ulceration at any thickness and thin melanoma thickness < 0.8 mm  
b: without ulceration and thin melanoma thickness > 0.8 mm ≤ 1 mm  
b: with ulceration at any thickness of thin or thick melanoma
The latest reviews on thin melanoma (TM) contin-
ue to consider it a melanoma within 1 mm in thickness, 
but no consensus exists as to which patients with TM 
are at risk for lymph node metastases (1). Numerous 
studies have evaluated the impact of various predic-
tors (Breslow thickness, Clark level, ulceration, regres-
sion, vascular invasion, mitotic activity, location, sex) 
for nodal disease in melanoma, but the conclusions 
have not been homogenous (2,3). For this reason, we 
read the paper by Homolak et al. with great interest, 
where the authors examine the sentinel lymph node 
biopsies (SLNB) of 184 patients affected by mela-
noma of thickness less than 1.5 mm, defined as thin 
(4). SLNB was positive in 22 patients (12%), and 30 
patients (7.65%) developed metastatic disease. The 
group of thinnest tumors (<0.50 mm) had the high-
est proportion of positive nodes (33%); the group of 
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thickest tumors (1.26-1.50 mm) had the highest pro-
portion of patients with metastatic disease (23%). The 
authors divided TM into 5 groups: 1) <0.50 mm (15 
patients, 5 with positive SLNB); 2) 0.50-0.75 mm (18 
patients, 3 with positive SLNB); 3) 0.76-1.00 mm (67 
patients, 7 with positive SLNB); 4) 1.01-1.25 mm (45 
patients, 4 with positive SLNB); 5) 1.26-1.50 mm (36 
patients, 3 with positive SLNB). The current staging 
system of the American Joint Committee on Cancer 
(AJCC) uses Breslow thickness as the primary attri-
bute, and up to 1 mm thick melanoma is defined as 
‘thin’ because it shows a good prognosis after surgical 
excision, with a 10-year survival rate of 85-90% in case 
of a tumor-free margin of at least 1 cm (5). Based on 
our experience, this limit should be maintained at 1 
mm because TM includes four main histological sub-
types, which reflect specific biological attitudes: the 
Prognostic Predictors of Thin Melanoma in  
Clinico-Pathological Practice
Table 1. The malignant melanocytic lesions of the skin can be subdivided, according to Breslow thickness, into thin 
melanoma (≤1 mm) or thick melanoma (>1 mm). The intra-epidermal radial growth phase and the micro-invasive radial 
growth phase without regression of thin melanoma are devoid of tumorigenic potential, while the micro-invasive radial 
growth phase with regression is burdened by an uncertain metastatic potential. The early invasive vertical growth phase 
of thin melanoma and the subcategories of the invasive vertical growth phase of thick melanoma all show tumorigenic 
potential, directly correlated to the depth of invasion and mitogenicity (pTis, pT1, pT2, pT3, pT4 and a/b specifications are 
adapted from the American Joint Committee on Cancer (AJCC) staging system)
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intra-epidermal (in situ) radial growth phase (rGP), 
the non-tumorigenic micro-invasive radial growth 
phase without regression, the micro-invasive radial 
growth phase with regression (>75%) of uncertain 
tumorigenic potential, and the tumorigenic early (≤1 
mm) invasive vertical growth phase (VGP) (6-10). This 
proposed sub-typing fits better with the AJCC stag-
ing system, as elucidated below and in Table 1: intra-
epidermal radial growth phase (pTis), micro-invasive 
radial growth phase without regression (pT1), micro-
invasive radial growth phase with regression (pT1), 
early invasive vertical growth phase (pT1), invasive 
vertical growth phase >1 mm, ≤2 mm (pT2), invasive 
vertical growth phase >2 mm, ≤4 mm (pT3), invasive 
vertical growth phase >4 mm (pT4). The in situ rGP 
and micro-invasive rGP without regression are bio-
logically indolent if completely removed, and SLNB 
is not necessary in these cases (6). in micro-invasive 
rGP with regression, performing SLNB is prudent, in 
particular if accompanied by high mitotic rates, while 
it is mandatory in early invasive VGP (7). Therefore, 
the prognostic predictors of nodal and distant metas-
tases require further research in the four above-men-
tioned histological subtypes of thin melanoma.
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